Ventyx Biosciences
NASDAQ · VTYX·Encinitas, CA·Small-cap·Phase 2
Clinical-stage biotech developing oral small molecules for inflammation. NLRP3 inhibitor portfolio (VTX3232 brain-penetrant, VTX2735 peripheral) plus selective TYK2 inhibitor (VTX958) and S1P modulator (tamuzimod). Announced acquisition by Eli Lilly in early 2026.
Decks (1)
| Title | Occasion | Date | Slides | Source |
|---|---|---|---|---|
| Ventyx Corporate Presentation | Corporate overview | October 22, 2025 | 30 |